Why physicians love COLONTOWN
Why do so many leading CRC clinicians and researchers love COLONTOWN?
Because they work with COLONTOWN patients and caregivers. Our patients are educated about their diseases, have strong support networks regardless of where they live, know where to get help with navigating their treatment plans and understand what questions to ask. A COLONTOWN patient is an empowered patient!
What you can find here...
Help your colorectal cancer patients get connected with thousands of others in 120+ support groups. Our programs also include an innovative suite of free education and training resources, all developed by patients and caregivers:
An online community with more than 120 private groups focused on all aspects of living with colorectal cancer. Managed by trained patient and caregiver admins with lived experience who ensure conversations are respectful and adhere to strict guidelines regarding evidence-based information.
Do your patients know where to start searching for clinical trials? This guided workshop gives stage IV MSS patients the tools they need to engage with clinical trial options.
The definitive guide for newly-diagnosed patients, created from thousands of patient experiences in the COLONTOWN community. CRC101 covers everything from common cancer lingo to what your first day of chemotherapy may look like to how to talk with your family about cancer. A must-read.
This Learning Center offers clear and detailed resources about biomarkers, including a side-by-side comparison of some of the newest testing options.
Home to COLONTOWN’s DocTalk video series, where researchers at the leading edge of CRC treatment provide insight and data directly to patients. We have live sessions where patients can ask questions, as well as a huge library of recorded talks.
A guide to everything patients need to know about how to make clinical trials work for them. We start at the very beginning and break down clinical trials from a patient treatment plan perspective.
Take a look at some of the questions community members had for Dr. Heinz-Josef Lenz of the Keck School of Medicine, USC at his recent DocTalk, “Targeting RAS Mutations in Colorectal Cancer”
- What does it mean if KRAS is never detected via liquid biopsies but always shows up in tissue biopsies?
- Can one expect similar impact of G12C inhibitors on appendiceal adenocarcinoma as on colorectal cancer?
- Does Dr. Lenz know of any resource we could reference to predict the effects of particular KRAS mutations? In the case of the rarer mutations in particular can this question be answered by the current literature? It is clear from talks given at the NCI KRAS symposium today that different mutations have very different effects.
Want to order patient materials?
We offer a selection of patient materials for your cancer center, including CRC QuickStart Guides, Physician Info Sheets and COLONTOWN Brochures.